In RA patients, TNF blocker treatment restored the suppressive activity of Tregs, which was associated with reduced protein phosphatase 1 (PP1) expression and increased Foxp3 phosphorylation in Tregs. The gene discussed is FOXP3; the disease is rheumatoid arthritis.